Related Experiment Video
Updated: Apr 3, 2026

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
Published on: September 23, 2021
Immunogenic cell death
Abhishek D Garg1, Aleksandra M Dudek-Peric, Erminia Romano
1Cell Death Research and Therapy (CDRT) Laboratory, Department for Cellular and Molecular Medicine, KULeuven University of Leuven, Leuven, Belgium.
Abstract:
Currently, it is widely acknowledged that a proactive anticancer immunosurveillance mechanism takes part in the rejection of neoplastic lesions before they progress towards a benign or malignant tumour. However in cases of very aggressive neoplastic lesions consisting of cells with high mutational diversity, cancer cell variants might be formed that are capable of evading host defence systems against uncontrolled proliferation and anticancer immunosurveillance. This is mainly accomplished through the exhibition of low immunogenicity, which is a particularly important stumbling block in the revival of long-lasting as well as stable anticancer immunity. Recently, it has emerged emphatically that inciting a cancer cell death routine, associated with the activation of danger signalling pathways evoking emission of damage-associated molecular patterns (DAMPs), markedly increases the immunogenicity of dying cancer cells. This cell death pathway has been termed "immunogenic cell death" (ICD). In the present review we introduce this concept and discuss its characteristics in detail. We also discuss in detail the various molecular, immunological and operational determinants of ICD.
Insights
Cancer cells can evade immune responses by reducing their immunogenicity. Inducing immunogenic cell death (ICD) enhances cancer cell visibility to the immune system, promoting anticancer immunity.
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- Anticancer immunosurveillance normally rejects early neoplastic lesions.
- Aggressive cancers with high mutational diversity can evade immune detection.
- Low immunogenicity is a key mechanism for cancer immune evasion.
Purpose of the Study:
- To introduce and detail the concept of immunogenic cell death (ICD).
- To discuss the characteristics of ICD.
- To explore the determinants of ICD.
Main Methods:
- Review of current scientific literature on cancer immunology and cell death.
- Detailed analysis of molecular and immunological pathways involved in ICD.
- Discussion of operational aspects of inducing ICD.
Main Results:
- Immunogenic cell death (ICD) involves cancer cell death pathways that activate danger signaling.
- ICD triggers the release of damage-associated molecular patterns (DAMPs).
- ICD significantly enhances the immunogenicity of dying cancer cells.
Conclusions:
- ICD represents a promising strategy to overcome cancer immune evasion.
- Understanding ICD determinants is crucial for developing effective cancer immunotherapies.
- Targeting ICD can potentially restore and stabilize anticancer immunity.
Related Concept Videos
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
Cells of the Innate Immune Response
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
The Extrinsic Apoptotic Pathway
Cell-mediated Immune Responses

